Prime Medicine, Inc. Revenue
Prime Medicine, Inc. (PRME) reported Revenue of $4.63 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-03-03
- Prime Medicine, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $838.00K, a 61.61% decline year-over-year.
- Prime Medicine, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $1.23M, a 486.12% increase year-over-year.
- Prime Medicine, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $1.11M.
- Prime Medicine, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $1.45M, a 146.02% increase year-over-year.
- Prime Medicine, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $4.63M, a 55.28% increase from fiscal 2024.
- Prime Medicine, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $2.98M.
- Prime Medicine, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $0.00.
- Prime Medicine, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $838.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.06M derived: sum of 2 quarters · filed 2026-03-03 | $3.18M derived: sum of 3 quarters · filed 2026-03-03 | $4.63M 10-K · filed 2026-03-03 |
| 2025-09-30 | $1.23M 10-Q · filed 2025-11-07 | $2.34M derived: sum of 2 quarters · filed 2025-11-07 | $3.79M 10-Q · filed 2025-11-07 | $5.98M derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-06-30 | $1.11M 10-Q · filed 2025-08-07 | $2.57M 10-Q · filed 2025-08-07 | $4.75M derived: sum of 3 quarters · filed 2026-03-03 | $4.96M derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-03-31 | $1.45M 10-Q · filed 2025-05-08 | $3.64M derived: sum of 2 quarters · filed 2026-03-03 | $3.85M derived: sum of 3 quarters · filed 2026-03-03 | $3.85M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.39M derived: sum of 2 quarters · filed 2026-03-03 | $2.39M derived: sum of 3 quarters · filed 2026-03-03 | $2.98M 10-K · filed 2026-03-03 |
| 2024-09-30 | $209.00K 10-Q · filed 2025-11-07 | $209.00K derived: sum of 2 quarters · filed 2025-11-07 | $800.00K 10-Q · filed 2025-11-07 | $800.00K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $591.00K 10-Q · filed 2025-08-07 | $591.00K derived: sum of 3 quarters · filed 2025-08-07 | $591.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $591.00K 10-Q · filed 2025-05-08 | $591.00K derived: sum of 2 quarters · filed 2025-05-08 | $591.00K derived: sum of 3 quarters · filed 2025-05-08 | $591.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 derived: sum of 3 quarters · filed 2025-02-28 | $0.00 10-K · filed 2025-02-28 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-03-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-09 | |||
| 2020-12-31 | $5.21M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |